Obstetric and Gynecologic Imaging

Should You Order MRI for Routine Ovarian Cancer Surveillance in an Asymptomatic Patient?

·
Should You Order MRI for Routine Ovarian Cancer Surveillance in an Asymptomatic Patient?

It’s a Tuesday afternoon clinic, and you are seeing a 58-year-old woman for her one-year follow-up visit after completing primary treatment for Stage IIIC high-grade serous ovarian cancer. She feels well, her physical exam is unremarkable, and her CA-125 level is stable within the normal range. She has no new complaints. You now face the clinical question of whether to order imaging for routine surveillance, and if so, which study provides the most value while minimizing harm. This article details the American College of Radiology (ACR) Appropriateness Criteria workflow for this specific scenario: an asymptomatic adult patient undergoing routine posttreatment surveillance for ovarian cancer with no suspected recurrence. For this presentation, the ACR rates MRI abdomen and pelvis without and with IV contrast as May be appropriate.

Who Fits This Clinical Scenario for Ovarian Cancer Surveillance?

This guidance applies specifically to adult patients with a history of treated ovarian cancer who are now in the routine surveillance phase. The key inclusion criteria are that the patient is completely asymptomatic and there is no clinical or biochemical suspicion of recurrence. This means no new pelvic pain, bloating, or constitutional symptoms, and tumor markers like CA-125 are stable and not rising. This workflow is intended for scheduled, routine follow-up.

It is critical to distinguish this scenario from similar but distinct clinical situations that require a different imaging approach. This guidance does not apply to:

  • Patients with suspected recurrence: If a patient presents with new symptoms (e.g., abdominal pain, ascites), a palpable mass on exam, or a rising CA-125 level, they fit the “Posttreatment evaluation. Suspected or known recurrence” scenario, which has a different set of imaging recommendations.
  • Patients undergoing initial staging: This workflow is not for newly diagnosed patients who have not yet undergone treatment. That presentation falls under the “Pretreatment staging” scenario.
  • Patients undergoing immediate posttreatment evaluation: Imaging performed shortly after a course of chemotherapy or radiation to assess the initial response to therapy is covered by the “Posttreatment response evaluation” scenario.

Correctly identifying your patient’s clinical context is the first step to selecting the most appropriate imaging study.

What Are You Looking For in Routine Posttreatment Surveillance?

The primary objective of surveillance imaging in an asymptomatic patient is the early detection of subclinical recurrent disease before it causes symptoms, with the hope that earlier treatment may improve outcomes. The differential in this context is narrow and focused on identifying patterns of ovarian cancer recurrence.

Peritoneal Carcinomatosis: This is the most common pattern of recurrence for epithelial ovarian cancer. The goal of imaging is to detect small tumor implants studding the peritoneal surfaces, omentum, and bowel serosa. These can be subtle and difficult to distinguish from normal structures or post-surgical changes, making high-resolution imaging essential.

Nodal Recurrence: The cancer can recur in the pelvic, para-aortic, or other retroperitoneal lymph nodes. Imaging aims to identify new or enlarging lymph nodes that are suspicious for metastatic involvement.

Parenchymal Organ Metastases: While less common than peritoneal or nodal recurrence, ovarian cancer can recur in solid organs, most frequently the liver or spleen. Surveillance imaging should be capable of assessing these organs for new lesions.

Differentiating Recurrence from Post-treatment Changes: A significant diagnostic challenge is distinguishing true recurrence from benign post-surgical changes, such as fibrosis, adhesions, and benign fluid collections. The ideal imaging modality should provide sufficient detail to help make this distinction.

Why Is MRI of the Abdomen and Pelvis a Key Option for This Surveillance Scenario?

For an asymptomatic patient undergoing routine ovarian cancer surveillance, the ACR panel rates MRI abdomen and pelvis without and with IV contrast as May be appropriate. The term “May be appropriate” reflects the ongoing debate in gynecologic oncology regarding the utility of routine surveillance imaging in asymptomatic patients, as a clear survival benefit has not been consistently demonstrated. However, when imaging is chosen, MRI offers distinct advantages.

The primary rationale for using MRI is its superior soft-tissue contrast resolution compared to other modalities. This is particularly valuable for detecting small-volume peritoneal disease, which can appear as subtle soft tissue thickening or tiny nodules. Modalities like diffusion-weighted imaging (DWI), a standard component of an MRI protocol for this indication, can increase the conspicuity of cellular tumors, helping to differentiate small recurrent implants from benign post-treatment fibrosis or fluid.

A crucial benefit of MRI is the complete absence of ionizing radiation (Adult RRL: O 0 mSv). For patients who may undergo multiple surveillance scans over many years, minimizing cumulative radiation exposure is a significant clinical consideration. The use of IV gadolinium-based contrast enhances the detection of peritoneal implants and assesses the vascularity of any suspicious findings.

Comparison to Other Modalities:

  • CT abdomen and pelvis with IV contrast: Also rated May be appropriate, CT is a valid alternative. It is generally faster and more widely available than MRI. However, its soft-tissue resolution is inferior for detecting subtle peritoneal disease, and it involves ionizing radiation (Adult RRL: ☢☢☢ 1-10 mSv). It is often used when MRI is contraindicated (e.g., incompatible implants) or not readily accessible.
  • FDG-PET/CT: While also rated May be appropriate, PET/CT is typically reserved for situations with a higher suspicion of recurrence rather than routine screening. It offers high sensitivity for metabolically active disease but comes with a significantly higher radiation dose (Adult RRL: ☢☢☢☢ 10-30 mSv) and a risk of false-positive findings from post-treatment inflammation.
  • Ultrasound (transabdominal or transvaginal): These are rated Usually not appropriate for this scenario. While excellent for evaluating the adnexa in a pre-treatment setting, ultrasound has a limited field of view and poor sensitivity for detecting the small-volume peritoneal and nodal disease that characterizes early recurrence throughout the abdomen and pelvis.

What’s Next After MRI abdomen and pelvis without and with IV contrast? Downstream Workflow

The results of the surveillance MRI will guide the next steps in management, which should always be determined in a multidisciplinary setting.

  • If the study is unequivocally positive for recurrence: A finding of clear peritoneal carcinomatosis, enlarging lymph nodes, or new visceral metastases confirms recurrent disease. The next step is typically a discussion with the patient about treatment options, which may include systemic therapy (chemotherapy, targeted agents), consideration for secondary cytoreductive surgery, or clinical trial enrollment. A biopsy may be pursued to confirm recurrence and obtain tissue for molecular testing, especially if there is a long disease-free interval.
  • If the study is unequivocally negative: A negative scan provides reassurance. The patient would typically continue with their established surveillance schedule, which includes regular clinical visits and monitoring of tumor markers. No further immediate action is needed.
  • If the study is indeterminate or equivocal: Findings such as subtle peritoneal thickening, a small stable nodule, or a borderline-sized lymph node can be challenging. In this situation, several options exist. One approach is a short-interval follow-up scan (often with the same modality, MRI) in 3-6 months to assess for change. Alternatively, if there is a single accessible lesion of high suspicion, a biopsy may be considered. If clinical suspicion rises (e.g., a subtle increase in CA-125), proceeding to FDG-PET/CT may be appropriate to assess for metabolic activity.

Pitfalls to Avoid (and When to Get Help)

When ordering and interpreting imaging for ovarian cancer surveillance, several common pitfalls can compromise diagnostic accuracy.

  • Not providing adequate clinical history: The radiologist’s interpretation is heavily dependent on knowing the patient’s primary cancer histology, treatment history (surgery, chemotherapy, radiation), and time since treatment. This context is crucial for differentiating recurrence from expected post-treatment changes.
  • Choosing the wrong modality: Opting for ultrasound for comprehensive surveillance is a common error; it is insensitive to the most common sites of recurrence. Similarly, using non-contrast CT significantly limits the ability to detect peritoneal disease.
  • Misinterpreting post-surgical changes: Benign granulation tissue, fibrosis, and surgical clips can all mimic or obscure recurrent disease. Comparing with prior imaging studies is essential to avoid this pitfall.

If a surveillance scan shows subtle or equivocal findings that do not clearly fit with either benign changes or definite recurrence, escalation is warranted. This should involve discussion at a multidisciplinary tumor board with input from gynecologic oncology, radiology, and pathology to form a consensus plan for management.

Related ACR Topics and Tools

For a comprehensive overview of imaging across all clinical presentations of this condition, refer to the parent topic article. For additional resources on selecting appropriate studies and understanding imaging techniques, the following tools are available.

Frequently Asked Questions

Why is MRI rated ‘May be appropriate’ instead of ‘Usually appropriate’ for routine surveillance?

The ‘May be appropriate’ rating reflects the lack of definitive evidence from large clinical trials showing that routine imaging of asymptomatic patients improves overall survival. While imaging can detect recurrence earlier, it’s not yet proven that treating subclinical, imaging-detected recurrence leads to better long-term outcomes than waiting for symptoms or a rise in CA-125. Therefore, the decision to perform surveillance imaging is often individualized based on physician and patient preference.

If my patient has a contraindication to MRI, is CT a good alternative?

Yes. CT of the abdomen and pelvis with IV contrast is also rated ‘May be appropriate’ by the ACR for this scenario. It is a very reasonable alternative for patients with contraindications to MRI (e.g., certain pacemakers, cochlear implants) or in situations where MRI is not readily available. While its soft-tissue contrast is lower than MRI’s, it is still a powerful tool for detecting nodal and visceral recurrence.

Should I order a non-contrast MRI if my patient has severe chronic kidney disease?

An MRI of the abdomen and pelvis without IV contrast is also rated ‘May be appropriate’. While gadolinium-based contrast agents improve the detection of small peritoneal implants, a non-contrast study, particularly one that includes diffusion-weighted imaging (DWI), can still provide valuable information and is superior to not performing imaging at all. It is a reasonable choice in patients with a contraindication to IV contrast.

How often should routine surveillance imaging be performed?

There is no universal consensus on the optimal frequency of surveillance imaging. Guidelines from organizations like the National Comprehensive Cancer Network (NCCN) and the Society of Gynecologic Oncology (SGO) suggest that imaging should be performed for symptoms or other clinical concerns, but do not mandate a fixed schedule for asymptomatic patients. If a surveillance strategy is adopted, intervals often range from every 6 to 12 months, but this should be tailored to the individual patient’s risk of recurrence and treatment history.

Does a normal CA-125 level mean I can skip surveillance imaging?

Not necessarily. While a normal and stable CA-125 is very reassuring, a subset of ovarian cancer recurrences (up to 20%) can occur without an elevation in this tumor marker. The decision to image should be based on a combination of factors, including the patient’s original tumor histology, symptoms, physical exam, and the shared decision-making process between the clinician and patient, not solely on the CA-125 level.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 30, 2026